Results 81 to 90 of about 5,649 (188)

RETRACTED: ESMO Guidance for reporting oncology real-world evidence (GROW)

Реальная клиническая практика: данные и доказательства
RETRACTED ARTICLEThe European Society for Medical Oncology (ESMO) has produced the very first expert-based guidance for reporting real-world evidence (RWE) studies specifically for oncology.
A. Sh. Motrinchuk, A. A. Kurylev
doaj   +1 more source

Healthcare Resource Utilization and Cost After Temperature‐Controlled Radiofrequency Treatment of Nasal Airway Obstruction: A Real‐World Longitudinal Claims Analysis

International Forum of Allergy &Rhinology, Volume 16, Issue 3, Page 261-271, March 2026.
ABSTRACT Background Nasal airway obstruction (NAO) is prevalent with substantial health and quality of life burdens. Nasal valve collapse (NVC) is one structural cause of NAO. Temperature‐controlled radiofrequency (TCRF) nasal valve remodeling offers an alternative to invasive surgery.
David W. Kennedy, Gavin Setzen, Ashleigh A. Halderman, Kevin C. Welch, Bobby Tajudeen, Gary M. Owens, Paul J. Niklewski, Masayoshi Takashima   +7 more
wiley   +1 more source

Biomarkers of Drug‐Induced Kidney Injury: Use in Clinical Trials and Recent Examples of Impact on Drug Development

Clinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 608-617, March 2026.
This manuscript describes the scope of implementation and impact of a regulatory agency‐qualified panel of six urine biomarkers on drug development, the process for which was conducted and funded by the Critical Path Institute, the Foundation for the National Institutes of Health, and the United States Food and Drug Administration.
Tanja S. Zabka, Michael Lawton, Tom Chu, Gary S. Friedman, Katrina Peron, Stefan R. Sultana, Warren E. Glaab, Nicholas M. P. King   +7 more
wiley   +1 more source

Resolution based on the results of the V annual scientific-practical conference "RWD/RWE. Possible and real"

Реальная клиническая практика: данные и доказательства
On September 19, 2024, in Moscow (Russian Federation), the V annual scientific-practical conference with international participation "RWD/RWE. Possible and Real" were organized and held.
A. S. Kolbin, M. A. Borzova, D. Yu. Belousov, V. V. Kalinichenko   +3 more
doaj   +1 more source

Reuse of Water as Part of a Water Sustainability Strategy: Experiences of Germany and Poland

Corporate Social Responsibility and Environmental Management, Volume 33, Issue 2, Page 2634-2648, March 2026.
ABSTRACT Wastewater can provide an alternative supply of scarce water resources, particularly for operations that do not require high‐quality water. The uptake in wastewater usage is likely to be driven by a combination of public and private sector actors via internal actions and external collaborations.
Jonathan Morris, T. Bartosz Kalinowski, Piotr C. Sosnowski, Katarzyna Paweska, Agata Rudnicka, Serena Caucci   +5 more
wiley   +1 more source

RWE in Europe – An Analysis

Journal of Health Policy & Outcomes Research, 2018
Background – This paper outlines findings from four roundtable discussions involving a number of stakeholders. They aimed to improve understanding of the use of real world evidence (RWE) across Europe. They focused on the development of a three-year roadmap for the increased incorporation of RWE, increasingly recognized as a valuable source of ...
openaire   +1 more source

Reshaping study design for faster extrapolation‐based drug approval in pediatric inflammatory bowel diseases: An ESPGHAN–NASPGHAN position paper

Journal of Pediatric Gastroenterology and Nutrition, Volume 82, Issue 3, Page 867-894, March 2026.
Abstract Children with inflammatory bowel diseases (IBD) have limited access to the available advanced therapies, given the lengthy gap between adult and pediatric approval. We aimed to review key hurdles for pediatric trials and recommend practical solutions.
Dan Turner, Amit Assa, Mikkel Malham, Shira Yuval Bar‐Asher, Carla Rayan, Jeffrey S. Hyams, Holm H. Uhlig, Brad Pasternak, David C. Wilson, Hilary K. Michel, Lissy de Ridder, Eric Zuckerman, Marina Aloi, Peter Szitanyi, Marla C. Dubinsky, Anne M. Griffiths, Roberto Saldana, Javier Martín‐de‐Carpi, Eytan Wine, Richard K. Russell, Jeremy Adler, Joseph Picoraro   +21 more
wiley   +1 more source

Real-world evidence reported for clinical efficacy evaluation in European Public Assessment Reports of authorised targeted therapies for solid malignancies: a comprehensive review (2018-2022)

ESMO Real World Data and Digital Oncology
Background: The role of real-world evidence (RWE) for clinical efficacy regulatory evaluation remains unclear. We aimed to assess and describe the reported use of RWE for clinical efficacy evaluation of authorised targeted therapies for treatment of ...
J.W.G. Derksen, D. Martins-Branco, A. Valachis, A. Pellat, S.C.M.W. van Nassau, A. Aggarwal, G. Pentheroudakis, M. Koopman, L. Castelo-Branco, S. Delaloge   +9 more
doaj   +1 more source

Safety of Baricitinib for the Treatment of Atopic Dermatitis in Adults Over a Median of 1.6 and up to 4.6 Years Treatment: Final Integrated Analysis of Eight Clinical Trials

JEADV Clinical Practice, Volume 5, Issue 1, Page 67-74, March 2026.
ABSTRACT Background Baricitinib is a selective Janus kinase (JAK)1/JAK2 inhibitor approved in more than 70 countries for the treatment of moderate‐to‐severe atopic dermatitis (AD) in adults, and in over 30 countries for adolescents and children from age 2 years with moderate‐to‐severe AD, who are candidates for systemic therapy.
Antonio Costanzo, Antonio Torrelo, Eric L. Simpson, Marjolein De Bruin‐Weller, Diamant Thaçi, Norito Katoh, Silvia Sabatino, Andrew Buchanan, Kasia Morawska, Samuel Ogwu, Karen Denning, Jonathan I. Silverberg   +11 more
wiley   +1 more source

Early Cancer Detection: What's Going on and What's Next

MedComm, Volume 7, Issue 3, March 2026.
Multicancer early detection (MCED) platforms have emerged as a promising strategy for the safe and effective early detection of multiple cancer types, with the potential to reduce metastatic burden and improve clinical outcomes, particularly for aggressive malignancies that lack effective population‐level screening.
Emma Di Carlo
wiley   +1 more source